Immunoglobulin E specific for Lolium perenne pollen allergens (sIgE (Lolium perenne))

Immunoglobulin E (IgE) specific for Lolium perenne (perennial ryegrass) pollen allergens is a specialized antibody that mediates Type I hypersensitivity reactions in sensitized individuals. These antibodies recognize specific proteins within ryegrass pollen, such as Lol p 1 and Lol p 5, which are major drivers of seasonal allergic rhinitis and asthma worldwide [1][2]. Upon inhalation of ryegrass pollen, these allergens cross-link the specific IgE molecules already bound to high-affinity FcεRI receptors on the surface of mast cells and basophils [3]. This cross-linking triggers the immediate degranulation of these cells, releasing inflammatory mediators like histamine and leukotrienes that cause sneezing, nasal congestion, and bronchoconstriction [3]. Therapeutic interventions targeting this pathway include anti-IgE monoclonal antibodies, which sequester free circulating IgE to prevent receptor binding, and allergen-specific immunotherapy (AIT), which aims to induce immune tolerance and shift the antibody profile toward protective IgG4 [4][5]. Monitoring specific IgE levels is essential for diagnosing ryegrass allergy and assessing the efficacy of desensitization treatments [6].

Other names

Ryegrass-specific IgEAnti-Lolium perenne IgELol p-specific IgEPerennial ryegrass pollen-specific IgE

Monoclonal antibodies like omalizumab bind to the Cε3 domain of circulating IgE, preventing its interaction with the high-affinity IgE receptor (FcεRI) on mast cells and basophils. Allergen-specific immunotherapy (AIT) induces desensitization by promoting the production of allergen-specific IgG4 antibodies that compete with IgE for allergen binding and by modulating T-cell responses toward tolerance.